| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/02/2006 | US20060025369 Methods of inhibiting manganese-containing superoxide dismutase 2 (MnSOD) |
| 02/02/2006 | US20060025368 Growth hormone releasing hormone enhances vaccination response |
| 02/02/2006 | US20060025367 Adenovirus vectors encoding brain natriuretic peptide |
| 02/02/2006 | US20060025366 Short intefering sequences comprising 1,2-DiLinoleyloxy-N,N-dimethylaminopropane (DLinDMA) or 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA) for use in silencing target gene sequences |
| 02/02/2006 | US20060025365 Immunostimulatory oligonucleotide multimers |
| 02/02/2006 | US20060025364 Regulation of peritoneal healing and adhesion development |
| 02/02/2006 | US20060025363 Use of antisense oligonucleotides for the treatment of degenerative skin conditions |
| 02/02/2006 | US20060025362 Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation |
| 02/02/2006 | US20060025361 treating, preventing, inhibiting, or reducing obesity, insulin resistance, diabetes (eg. type II and type I diabetes); host cells; bioassays for identifying a component of a PTP-1B signal transduction pathway |
| 02/02/2006 | US20060025360 Human cervical cancer protooncogene and protein encoded therein |
| 02/02/2006 | US20060025356 28-epirapalogs |
| 02/02/2006 | US20060025341 Isolated polynucleotide encoding inhibin-related proteins for treating cancer of epithelial, testicular, ovarian, prostate; biodrug protein; activin binding activity; hormone inhibitor; muscle regeneration |
| 02/02/2006 | US20060025338 Compositions and methods for treatment of lymphatic and venous vessel arterialization |
| 02/02/2006 | US20060025337 Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
| 02/02/2006 | US20060025334 Vanilloid receptor-2 ligands for treating anxiety or depression |
| 02/02/2006 | US20060025330 Electrostatic bonding type macromolecular micelle drug carrier and drug carried thereon |
| 02/02/2006 | US20060024828 Process of making a compound by forming a polymer from a template drug |
| 02/02/2006 | US20060024820 Chromosome-based platforms |
| 02/02/2006 | US20060024798 Gene knockout; gene overexpression; liposomes |
| 02/02/2006 | US20060024795 Interferon-Like molecules and uses thereof |
| 02/02/2006 | US20060024788 Inducible alphaviral gene expression system |
| 02/02/2006 | US20060024754 Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 02/02/2006 | US20060024728 GM-CSF and/or defensin protein expression regulators in epithelial cells comprising ETS transcription factor or gene encoding the same |
| 02/02/2006 | US20060024727 Antisense modulation of C-reactive protein expression |
| 02/02/2006 | US20060024708 Porcine sulfotransferase 2A1 polynucleotide sequence, protein, and methods of use for same |
| 02/02/2006 | US20060024688 Alterations of fibulin genes in macular degeneration |
| 02/02/2006 | US20060024683 Transcription factor of MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances |
| 02/02/2006 | US20060024309 administering vascular endothelial growth factor (VEGF) antagonists such as VEGF fusion protein traps, nucleotides, antisense agents, lipids or carbohydrates, for decreased serum glucose levels, improved glucose tolerance, and/or improved glycemic control; antidiabetic agents |
| 02/02/2006 | US20060024299 Human osteoclast derived cathepsin |
| 02/02/2006 | US20060024280 Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis |
| 02/02/2006 | US20060024279 Retroviral vectors |
| 02/02/2006 | US20060024278 Methods and products related to the production of inner ear hair cells |
| 02/02/2006 | US20060024275 Methods for use of MPL ligands with primitive human stem cells |
| 02/02/2006 | US20060024274 Retroviral vectors |
| 02/02/2006 | US20060024273 Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
| 02/02/2006 | US20060024267 TNFr/OPG-like molecules and uses thereof |
| 02/02/2006 | US20060024240 Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes |
| 02/02/2006 | US20060024233 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 02/02/2006 | US20060024232 Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface |
| 02/02/2006 | DE19856463B4 Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren Retroviral pseudotyped with LCMV hybrid vectors |
| 02/02/2006 | CA2589098A1 Method for diagnosing and treating bone-related diseases |
| 02/02/2006 | CA2579753A1 Non-integrative and non-replicative lentivirus, preparation and uses thereof |
| 02/02/2006 | CA2574802A1 Specific inhibition of autoimmunity and diseases associated with autoantigens |
| 02/02/2006 | CA2574698A1 Addition of transgenes into adenoviral vectors |
| 02/01/2006 | EP1621626A1 AAV Vectors for the manufacture of medicaments for convection enhanced delivery |
| 02/01/2006 | EP1621625A2 AAV vectors for the manufacture of medicaments for convention enhanced delivery |
| 02/01/2006 | EP1621623A2 BASB029 polynucleotide(s) and polypeptides from Neisseria meningitis |
| 02/01/2006 | EP1621548A2 Polypeptides, CDNAs encoding the same and utilization thereof |
| 02/01/2006 | EP1621545A2 Oligoribonucleotides and ribonucleases for cleaving RNA |
| 02/01/2006 | EP1621213A1 Ocular gene therapy |
| 02/01/2006 | EP1621212A1 Formulations comprising antisense nucleotides to connexins |
| 02/01/2006 | EP1621208A1 DNA vaccination for treatment of autoimmune disease |
| 02/01/2006 | EP1620732A2 Claudins' underexpression as markers of tumor metastasis |
| 02/01/2006 | EP1620560A1 Delivery of sirna to cells using polyampholytes |
| 02/01/2006 | EP1620545A2 Disease prevention and vaccination following thymic reactivation |
| 02/01/2006 | EP1620544A2 MODIFIED iRNA AGENTS |
| 02/01/2006 | EP1620453A2 Modulation of glucagon receptor expression |
| 02/01/2006 | EP1620133A1 Gene therapy for neurometabolic disorders |
| 02/01/2006 | EP1620131A2 Ghrh for use in treating chronic renal failure |
| 02/01/2006 | EP1620126A2 Disease prevention and vaccination prior to thymic reactivations |
| 02/01/2006 | EP1620125A2 Tolerance to graft following thymic reactivation |
| 02/01/2006 | EP1620123A2 Genetic modification of targeted regions of the cardiac conduction system |
| 02/01/2006 | EP1620112A2 Desmoglein 4 is a novel gene involved in hair growth |
| 02/01/2006 | EP1619952A2 Tolerance to graft prior to thymic regeneration |
| 02/01/2006 | EP1619951A2 Methods and compositions for treating disorders |
| 02/01/2006 | EP1619949A2 Postnatal stem cells and uses thereof |
| 02/01/2006 | EP1461052A4 Nucleic acid injected into hepatic vein lumen and delivered to primate liver |
| 02/01/2006 | EP1223953B1 Matrix-targeted fusion polypeptides for tissue regeneration and wound healing |
| 02/01/2006 | EP1200479B1 Multiple cytokine-antibody complexes |
| 02/01/2006 | EP1129204B1 Novel system for regulating transgene expression |
| 02/01/2006 | EP1115849B1 Genes of the 1-desoxy-d-xylulose biosynthetic pathway |
| 02/01/2006 | EP1064402B1 Antisense modulation of lfa-3 |
| 02/01/2006 | EP1047448B1 Dna vaccines against tick-borne flaviviruses |
| 02/01/2006 | EP1026243B1 NUCLEIC ACID CAPABLE OF BINDING SPECIFICALLY TO Ras TARGET PROTEIN |
| 02/01/2006 | EP0996738B1 Recombinant vector containing infectious, viral genome sequences greater than 100 kb, method for producing same and use for the mutagenesis of the viral sequences |
| 02/01/2006 | EP0922056B1 New fibrinogen binding protein originating from coagulase-negative staphylococcus |
| 02/01/2006 | CN1729291A Exon 1beta of PDGF receptor alpha gene and utilization thereof |
| 02/01/2006 | CN1729019A Wild-type RAD as a cancer therapeutic agent |
| 02/01/2006 | CN1728946A Method of obtaining viable human liver cells, including hepatic stem/progenitor cells |
| 02/01/2006 | CN1727489A Bacterial plasmids |
| 02/01/2006 | CN1727486A cDNA library of differential expression gene in blood lymphocytes of SARS rehabilitated persons |
| 02/01/2006 | CN1727477A siRNA for restraining expression and proliferation of tumor and leukaemia cell VEGE and application |
| 02/01/2006 | CN1727362A Preparation and application of vaccine for curing tumor in positive carcino-embryonic antigen |
| 02/01/2006 | CN1239133C Medical device |
| 01/31/2006 | US6992170 Polypeptides and polynucleotides homologous to thymosin, ephrin a receptors, and fibromodulin |
| 01/31/2006 | US6992070 Treating tissue with phosphodiesterase inhibitor compound and administering exogenous nucleic acid |
| 01/31/2006 | US6991936 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 01/31/2006 | US6991935 Anticancer agents |
| 01/31/2006 | US6991787 expanding cells in culture, transfecting cells with an exogenous gene, and cryopreserving the cells; suitable for use in transplantation and gene therapy; storage stability |
| 01/31/2006 | US6991786 Anti-microbial biotherapeutic agents: alternatives to conventional pharmaceutical antibiotics |
| 01/31/2006 | CA2390104C Method for transfer of molecular substances with prokaryotic nucleic acid-binding proteins |
| 01/26/2006 | WO2006010041A2 Morpholino antisense drugs for human herpesvirus 8 |
| 01/26/2006 | WO2006009919A2 Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods |
| 01/26/2006 | WO2006009843A2 Negative regulation of hypoxia inducible factor 1 by os-9 |
| 01/26/2006 | WO2006009805A2 Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors |
| 01/26/2006 | WO2006009575A1 METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA |
| 01/26/2006 | WO2006008649A1 Anti-sense polynucleotide therapy for gastrin-promoted tumors |
| 01/26/2006 | WO2006008513A1 Modified virus |
| 01/26/2006 | WO2006008154A1 mRNA MIXTURE FOR VACCINATING AGAINST TUMORAL DISEASES |
| 01/26/2006 | WO2006008142A1 Diagnosis and therapy of psoriasis vulgaris |